## CONTENTS • INHOUD

<table>
<thead>
<tr>
<th>No.</th>
<th>Page No.</th>
<th>Gazette No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GOVERNMENT NOTICES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health, Department of</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Government Notices</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>339</td>
<td>Regulations relating to a transparent pricing system for medicines and scheduled substances: Determination of maximum increase in the single exit price of medicines and scheduled substances for the period up until 31 July 2008</td>
<td>3 30901</td>
</tr>
<tr>
<td>340</td>
<td>Medicines and Related Substances Act, 1965: Regulations relating to a transparent pricing system for medicines and scheduled substances: Information to be published by manufacturers and importers of medicines and scheduled substances before taking an increase in the single exit price</td>
<td>4 30901</td>
</tr>
</tbody>
</table>
REGULATIONS RELATING TO A TRANSPARENT PRICING SYSTEM FOR
MEDICINES AND SCHEDULED SUBSTANCES

DETERMINATION OF MAXIMUM INCREASE IN THE SINGLE EXIT PRICE OF
MEDICINES AND SCHEDULED SUBSTANCES FOR THE PERIOD UP UNTIL 31 JULY
2008

The Minister of Health has determined, in terms of Regulation 8(1) of the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette Number 28214 of 11 November 2005, that the single exit price as defined in the said Regulations, may be increased by no later than 01 July 2008 up to a maximum amount of 6.5% of the ex manufacturer price that prevailed at 01 January 2008.

An increase in the single exit price in terms of this Notice may only be taken by the manufacturer or importer of the relevant medicine or scheduled substance 30 days after the date that the manufacturer or importer has communicated the information required by the Director-General in terms of the Notice published by him under Regulation 21 of the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances.

M E TSHABALALA-MSIMANG
MINISTER OF HEALTH
MEDICINES AND RELATED SUBSTANCES ACT 1965

REGULATIONS RELATING TO A TRANSPARENT PRICING SYSTEM FOR MEDICINES AND SCHEDULED SUBSTANCES

INFORMATION TO BE PUBLISHED BY MANUFACTURERS AND IMPORTERS OF MEDICINES AND SCHEDULED SUBSTANCES BEFORE TAKING AN INCREASE IN THE SINGLE EXIT PRICE

The Director-General of Health has determined in accordance with Regulation 21 of the Regulations Relating to A Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette Number 28214 of 11 November 2005 that the following information in both electronic (Excel format) and document form must be communicated to the Directorate: Pharmaceutical Economic Evaluation within the National Department of Health by a manufacturer or importer of the medicine or scheduled substance in respect of which it intends to take an price increase:

1. NAPPI Code (9-digit);
2. Brand name;
3. Active ingredients;
4. Strength and dosage form
5. Pack size;
6. Ex-manufacturer price as at 01 January 2008;
7. New increased ex-manufacturer price
8. Logistic fee as at 01 January 2008
9. New increased logistic fee
10. Value Added Tax
11. New single exit price after the increase

MR. T. MSELEKU
DIRECTOR-GENERAL: HEALTH
DATE: 2008-03-19